That's a great question. We are doing the best we can with the tools currently at our disposal, but it's for that very reason that we are trying to move forward with these quite ambitious reforms that I alluded to.
I would say today, no, we are not doing a very good job, but it's because the landscape has changed so dramatically, as I also alluded to in my presentation. When the PMPRB was established, arguably those drugs we were regulating were within reach of the everyday consumer. They treated common ailments. They cost $100 to $1,000 a year. Eight of the 10 top-selling patented medicines are biologics, they're complicated, and so a whole different framework is necessary to—